Therapeutics
Page 16 to 32 of 80 |   < PREVIOUS PAGE   NEXT PAGE >
Stem Cells for cellular therapy space. By Dr Enal S. Razvi and Dr Gary M. Oosta Spring 10
This article explores the emerging market landscape vis--vis the use of stem cells as cellular therapeutics. For more than 40 years, hematopoietic stem cells have been utilised as cellular therapeutics in a number of malignant diseases as well as inborn genetic errors of metabolism.

Read More

Reshaping the landscape of cancer drug discovery and development. By Dr Paolo Paoletti Fall 2007
The landscape of cancer drug discovery and development is shifting, adjusting and reshaping itself in response to the huge rush of scientific knowledge which has come to the fore over the past few decades.

Read More

Human ES Cell Derived Functional Cells as Tools in Drug Discovery. Winter 2007 By Dr Petter Bjorquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner Winter 2007
The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for the pharmaceutical industry.

Read More

Opportunities in Gastroenterology. Winter 2007 By Dirk Reyn Winter 2007
Despite being one of the world's largest therapeutic areas and presenting huge burdens to healthcare and economies globally, many of the diseases of the gastrointestinal (GI) tract are not well understood and less than optimally treated.

Read More

Stem Cell Applications and Opportunities in Drug Discovery. Spring 09 By Dr Mark A. Thiede Spring 2009
The high attrition rate of late stage drug candidates has led the pharmaceutical and biotech industries to a reassess the in vitro models used to select and validate drug targets and subsequent lead molecules.

Read More

Is amyloid-related toxicity an inevitable consequence of ageing? Spring 08 By Dr J Mark Treherne and Dr David IC Scopes Spring 2008
Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related diseases succeed in the clinic.

Read More

Advances in antibody therapy take a promising new approach to how we treat cancer Spring 2008 By Dr Patrick A Baeuerle Spring 2008
Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited.

Read More

Building a robust portfolio of new medicines. Winter 08 By Dr Timothy N.C. Wells Winter 2008
Malaria is one of the biggest killers of our time. Current estimates from the World Health Organisation (WHO) suggest that more than 250 million people are at risk worldwide. More significantly, almost a million people die each year, of whom more than 700,000 are children under five. One of the ways to combat this disease is by developing new medicines.

Read More

Transcending Proteasome Inhibition for the Treatment of Cancer. Summer 08 By Dr Mark Rolfe Summer 2008
Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathway for controlling protein degradation is the ubiquitin proteasome system (UPS).

Read More

HIV Therapy past, present and future. Summer 08 By Dr Laura Waters Summer 2008
Since the identification of HIV in 1983 and licensing of AZT in 1986 we now have more than 20 agents available for HIV treatment from five drug classes. This article will review recent advances in HIV treatment and discuss future challenges that the research community, pharmaceutical industry, healthcare providers and HIV infected patients will need to address as time goes on.

Read More

Targeted remodelling of the diseased lung with biopharmaceutical agents. Fall 08 By Dr Edward E. Berger Fall 2008
Emphysema is a progressive, debilitating disease that affects approximately 4.1 million people in the United States or roughly 1% of the US population. The disease is characterised by destruction of lung tissue as a result of inflammation caused by exposure to noxious inhaled agents for extended periods.

Read More

Treating rheumatoid arthritis with DMARDs and biologics. Fall 08 By Dr William E. Fogler Fall 2008
Continuing research efforts that further refine our understanding of the pathobiological mechanisms in RA has, in turn, led to the development of novel DMARDs acting on these mechanisms.

Read More

Immunogenicity of therapeutic proteins. Summer 06 By Dr Ivo Van Walle, Dr Ignace Lasters and Philippe Stas Summer 2006
Therapeutic proteins enter the market in increasing numbers, and current observations confirm that most of these biopharmaceuticals are to a variable extent immunogenic.

Read More

Monoclonals - the billion dollar molecules of the future. Fall 06 By Dr Martin Wiles and Patrik Andreassen Fall 2006
In 1975, two British scientists thought of creating a mouse antibody that could be replicated or 'cloned' to produce identical copies. Identical copies with identical modes of action had the potential to be a drug. They had launched what was to be one of biotechnology's best ideas.

Read More

Enabling the promise of Stem Cells. Spring 11 By Robert Shaw and Dr Jeff Till Spring 2011
The remarkable potential of stem cells to generate several hundred differentiated cell types is driving their use for regenerative medicine and for supporting the traditional drug discovery and development process. However, sustained progress in these areas is dependent on advances in the ability to: grow these cells; direct, and control their differentiation; and produce the quantities needed for clinical trials and therapies in a cGMP (current Good Manufacturing Practices) environment. This article will examine advances taking place on both the lab bench and the pharmaceutical production floor that are helping to bring the promise of stem cells closer to reality.

Read More

New ways to optimise therapeutic and diagnostic antibodies. Winter 10 By Dr Markus Enzelberger Winter 2010
Monoclonal antibodies are the fastest-growing category of research within the biotech and pharmaceutical industries. Several monoclonal antibodies are listed in the top 10 selling blockbusters, and the market forecast predicts that the number of monoclonal antibodies within the top 10 will further increase1.

Read More

Therapeutics
Page 16 to 32 of 80 |   < PREVIOUS PAGE   NEXT PAGE >